X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
humans (15) 15
male (13) 13
female (12) 12
middle aged (12) 12
aged (11) 11
oncology (10) 10
adult (9) 9
cancer (9) 9
care and treatment (8) 8
aged, 80 and over (5) 5
head and neck cancer (4) 4
medicine & public health (4) 4
patients (4) 4
pharmacology & pharmacy (4) 4
renal-cell carcinoma (4) 4
research (4) 4
toxicity (4) 4
antineoplastic agents - therapeutic use (3) 3
cancer patients (3) 3
cancer therapies (3) 3
carcinoma, renal cell - drug therapy (3) 3
chemotherapy (3) 3
clinical trials (3) 3
fatigue (3) 3
head and neck neoplasms - therapy (3) 3
indoles - adverse effects (3) 3
internal medicine (3) 3
metastases (3) 3
metastasis (3) 3
neoplasms - drug therapy (3) 3
oncology, experimental (3) 3
pneumonitis (3) 3
protein kinase inhibitors - adverse effects (3) 3
pyrroles - adverse effects (3) 3
radiotherapy (3) 3
receptor (3) 3
sunitinib (3) 3
tumors (3) 3
analysis (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
breast cancer (2) 2
carcinoma, renal cell - pathology (2) 2
chemoradiation (2) 2
chemoradiotherapy (2) 2
chemoradiotherapy - adverse effects (2) 2
clear cell-type renal cell carcinoma (2) 2
cohort studies (2) 2
cross-sectional studies (2) 2
dosage and administration (2) 2
drug dosages (2) 2
dysphagia (2) 2
eating (2) 2
endothelial growth-factor (2) 2
enzymes (2) 2
erbb-2 protein (2) 2
everolimus (2) 2
head and neck neoplasms (2) 2
hematology, oncology and palliative medicine (2) 2
immunohistochemistry (2) 2
impact (2) 2
incidence (2) 2
indoles - administration & dosage (2) 2
indoles - therapeutic use (2) 2
kaplan-meier estimate (2) 2
kidney cancer (2) 2
kidney neoplasms - drug therapy (2) 2
kinases (2) 2
lymph-nodes (2) 2
mammalian target (2) 2
mortality (2) 2
neoplasm metastasis (2) 2
original (2) 2
original research article (2) 2
pharmacology/toxicology (2) 2
pharmacotherapy (2) 2
protein kinase inhibitors - administration & dosage (2) 2
pyrroles - administration & dosage (2) 2
pyrroles - therapeutic use (2) 2
renal failure (2) 2
risk assessment (2) 2
safety (2) 2
studies (2) 2
therapy (2) 2
tor protein (2) 2
treatment outcome (2) 2
trial (2) 2
tyrosine (2) 2
tyrosine kinase inhibitor (2) 2
4-beta-hydroxycholesterol (1) 1
abnormalities (1) 1
acute myocardial-infarction (1) 1
addictive behaviors (1) 1
administration, oral (1) 1
adolescent (1) 1
advanced solid tumors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BMC cancer, ISSN 1471-2407, 2014, Volume 14, Issue 1, pp. 219 - 219
Journal Article
International Journal of Cancer, ISSN 0020-7136, 2016, Volume 138, Issue 10, pp. 2312 - 2321
Mammalian target of rapamycin inhibitors (mTORi) have clinically significant activity against various malignancies, such as renal cell carcinoma and breast... 
toxicity | mTOR inhibitors | everolimus | interstitial lung disease | pneumonitis | MAMMALIAN TARGET | NONINFECTIOUS PNEUMONITIS | SIROLIMUS THERAPY | RENAL-CELL CARCINOMA | EVEROLIMUS THERAPY | SINGLE-AGENT | PNEUMOCYSTIS PNEUMONIA | ONCOLOGY | RANDOMIZED PHASE-II | TEMSIROLIMUS CCI-779 | ADVERSE EVENTS | Lung Diseases, Interstitial - etiology | Lung Diseases, Interstitial - metabolism | Humans | Risk Factors | Antineoplastic Agents - therapeutic use | Patient Outcome Assessment | Protein Kinase Inhibitors - adverse effects | Incidence | Neoplasms - drug therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplasms - complications | Lung Diseases, Interstitial - diagnosis | Lung Diseases, Interstitial - therapy | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Disease Management | Lung Diseases, Interstitial - epidemiology | Cancer patients | Care and treatment | Algorithms | Lung diseases | Cancer therapies | Mortality | TOR protein | Respiratory function | Toxicity | Lung cancer | Abnormalities | Breast cancer | Rapamycin | Management | Criteria | Disease control | Patients | Morbidity | Inhibitors | Differential diagnosis | Diagnostic systems | Diagnosis | Clear cell-type renal cell carcinoma | Cancer | Immune system | Kidney transplantation | Index Medicus
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2016, Volume 38, Issue 10, pp. 2286 - 2299
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Immunology Immunotherapy, ISSN 0340-7004, 2019, Volume 68, Issue 2, pp. 319 - 329
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and... 
mTOR | Cyclophosphamide | Everolimus | Tregs | IMMUNOLOGY | CANCER | TRIAL | LENVATINIB | THERAPY | ONCOLOGY | IMMUNE SUPPRESSION | REGULATORY T-CELLS | TYROSINE KINASE INHIBITOR | MODULATION | ENDOTHELIAL GROWTH-FACTOR | Cyclophosphamide - administration & dosage | Administration, Oral | Carcinoma, Renal Cell - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Anemia - chemically induced | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Everolimus - administration & dosage | Fatigue - chemically induced | Cyclophosphamide - adverse effects | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Everolimus - adverse effects | Adult | Anorexia - chemically induced | Female | Kidney Neoplasms - pathology | Aged | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Analysis | Clinical trials | Medicine, Experimental | Dosage and administration | Metastasis | T cells | Cancer | TOR protein | Cell survival | Immune response | Immunoregulation | Toxicity | Fatigue | Lymphocytes T | Patients | Metastases | Angiogenesis | Immunosuppression | Pneumonitis | Antitumor activity | Clear cell-type renal cell carcinoma | Index Medicus | Clinical Trial Report
Journal Article
Journal Article